Oelrich said there was also no reason to split Bayer, whose businesses span agrochemicals, pharmaceuticals and non-prescription drugs. "We function with three very independent businesses," he said.

Bayer expects its pharmaceutical business to return to growth in 2027, unit President Stefan Oelrich said Monday. The German conglomerate is planning to launch new therapies — one that treats a ...

Despite challenges in the Crop Science division, the strength of the Pharmaceuticals division and steady performance in Consumer Health are encouraging. Moreover, Bayer recently scored an ...

The German pharmaceutical company has tied up ... a better future with increased collaboration across the healthcare ecosystem.” Bayer’s deal with Genpact opens up new ground for pharma ...

German pharmaceutical giant Bayer released its ... innovators like Impli to explore the exciting frontiers of making health ...

Berenberg Bank analyst Sebastian Bray maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €22.00. The ...

Bayer's venerable testosterone replacement product for men with hypogonadism – Nebido – is being sold to Grünenthal as the group continues a revamp of its healthcare business. Grünenthal is ...

The pharmaceutical company’s latest partnership with Incremental and Skai drove a 32% boost in iROI, delivering nearly a third more sales per ad dollar.

With over 26 years of distinguished experience in the healthcare and pharmaceutical industry, Bradley's leadership will play a pivotal role in advancing Bayer's presence and growth in Thailand ...

It aspires to be seen as a partner of choice for key customers in priority markets by creating best-in-class joint business opportunities that provide a win for Bayer, its customers, the category and ...